IP Library Granted Patent US 8,153,149
Granted Patent B2
US 8,153,149 · App. 11/888,658 · Granted Apr 10, 2012

Controlled delivery system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,149
App. No.
11/888,658
Granted
Apr 10, 2012
Kind
B2
Abstract

The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.

Claims (8)

1. A pharmaceutical composition for providing sustained local anaesthesia after administration to a subject, said composition comprising:

about 66% by weight sucrose acetate isobutyrate (SAIB) liquid carrier material relative to the total weight of the composition;

about 12% by weight bupivacaine relative to the total weight of the composition; and

about 22% by weight benzyl alcohol (BA) relative to the total weight of the composition,

wherein the bupivacaine is released from the composition for a period of at least 24 hours after administration in an amount sufficient to provide sustained local anesthesia.

2. The composition of claim 1 , wherein the bupivacaine is present in free base form.

3. The composition of claim 1 , wherein said composition is suitable for topical, systemic, or parenteral administration.

4. The composition of claim 1 , wherein said composition is suitable for administration via injection, pouring, spraying, dipping, aerosolizing, or via a coating applicator.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2022
From: LEE, MIN L.; MIKSZTAL, ANDREW R.
To: DURECT CORPORATION
Reel/Frame 059990/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2009
From: VERITY, A. NEIL
To: DURECT CORPORATION
Reel/Frame 023597/0805 →